Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (28937)	6/23/1999 10:23:00 PM
From: TomOrt	Read Replies (1) \| Respond to of 32384

Henry; Congradulations to you on a big step forward for Ligand, as the pieces begin to fall in place. You have worked hard to keep us all informed ( even though the children who want to get rich overnight can't see it ) but you are greatly appreciated. The future looks a little brighter, and is easier to envision today than yesterday. Thanks again; TomOrt

To: Henry Niman who wrote (28937)	6/23/1999 10:41:00 PM
From: bob zagorin	Respond to of 32384

thanks for the explanation. let me see if i understand. we should be happy when hear about raloxifene developments because that may be complimentary to LGND's technology. is that right? TIA.

To: Henry Niman who wrote (28937)	6/23/1999 11:05:00 PM
From: WTDEC	Read Replies (4) \| Respond to of 32384

Henry, when you get a chance could you please explain what the two percentages after [C.I.] in the following quote means? "At the initial dose level of 300 mg/m2/day proposed for marketing, Targretin capsules produced at least 50% improvement (partial response or clinical complete response) in 48% (40/84, 95% confidence intervals [C.I.] 37% to 58%) of patients" Also, it appears to me that approval of Targretin won't quite be the 'slam-dunk' that Panretin gel was. Your thoughts on the chances for approval would be appreciated. Best regards, Walter